Zacks: Brokerages Expect Y-mAbs Therapeutics, Inc (YMAB) Will Post Earnings of -$0.44 Per Share

Share on StockTwits

Wall Street analysts expect Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) to announce earnings per share of ($0.44) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Y-mAbs Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.53) and the highest estimate coming in at ($0.34). The company is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Y-mAbs Therapeutics will report full-year earnings of ($1.53) per share for the current fiscal year, with EPS estimates ranging from ($1.70) to ($1.35). For the next fiscal year, analysts forecast that the business will post earnings of ($1.77) per share, with EPS estimates ranging from ($2.22) to ($1.31). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Y-mAbs Therapeutics.

A number of brokerages have recently weighed in on YMAB. BTIG Research began coverage on Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $35.00 target price on the stock. Cowen restated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Tuesday, October 16th. Canaccord Genuity began coverage on Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Bank of America began coverage on Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $26.00 target price on the stock.

In other Y-mAbs Therapeutics news, Director Ashu Tyagi bought 430,174 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $6,882,784.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director James Healy bought 500,000 shares of the business’s stock in a transaction dated Friday, September 21st. The stock was acquired at an average price of $16.00 per share, for a total transaction of $8,000,000.00. The disclosure for this purchase can be found here. Insiders bought a total of 961,424 shares of company stock worth $15,382,784 in the last 90 days.

A number of institutional investors have recently bought and sold shares of the stock. Dean Capital Investments Management LLC purchased a new position in Y-mAbs Therapeutics in the third quarter valued at approximately $664,000. FMR LLC purchased a new position in Y-mAbs Therapeutics in the third quarter valued at approximately $32,686,000. Artal Group S.A. purchased a new position in Y-mAbs Therapeutics in the third quarter valued at approximately $3,984,000. BlackRock Inc. purchased a new position in Y-mAbs Therapeutics in the third quarter valued at approximately $398,000. Finally, Alliancebernstein L.P. purchased a new position in Y-mAbs Therapeutics in the third quarter valued at approximately $8,632,000.

Shares of YMAB opened at $25.53 on Friday. Y-mAbs Therapeutics has a 52 week low of $18.00 and a 52 week high of $31.00.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: Inflation

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply